Safety and Immune Responses to a DNA‐Based Human Immunodeficiency Virus (HIV) Type I Env/Rev Vaccine in HIV‐Infected Recipients: Follow‐up Data

Abstract

We recently reported the safety and immunologic response to a DNA vaccine containing env/rev in a group of untreated healthy human immunodeficiency virus (HIV)-infected subjects with CD4 lymphocyte counts μL [1]. No significant adverse experiences occurred, with some evidence for antibody responses and occasional cell-mediated immune responses. We now report an additional cohort immunized with a 300-μg dose by jet injection (JI) or by needle (N), follow-up safety data over <2.5 years for the whole cohort, and results of boosting with 1 mg of vaccine.